Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies

Blood

Volumn 117, Issue 25, 2011, Pages 6963-6970

  Soiffer, Robert J ^a   LeRademacher, Jennifer ^b   Ho, Vincent ^a   Kan, Fangyu ^c   Artz, Andrew ^d   Champlin, Richard E ^e   Devine, Steven ^f   Isola, Luis ^g   Lazarus, Hillard M ^h   Marks, David I ⁱ   Porter, David L ^j   Waller, Edmund K ^k   Horowitz, Mary M ^b   Eapen, Mary ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c NATIONAL MARROW DONOR PROGRAM   (United States)

^d UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g MOUNT SINAI HOSPITAL   (United States)

^h CASE WESTERN RESERVE UNIVERSITY   (United States)

ⁱ UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k EMORY UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; MELPHALAN; THYMOCYTE ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; DISEASE FREE SURVIVAL; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HODGKIN DISEASE; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MORTALITY; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RELAPSE; T CELL DEPLETION;

EID: 79959496711     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-01-332007     Document Type: Article

References (21)

1. Johnston L. Acute graft-versus-host disease: differing risk with differing graft sources and conditioning intensity. Best Pract Res Clin Haematol. 2008;21(12):177-192. (Pubitemid 351712712)
2. Chakraverty R, Peggs K, Chopra R, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood. 2002;99(3):1071-1078. (Pubitemid 34525573)
3. Lee SJ, Klein JP, Haagenson M, et al. High resolution donor recipient HLA-matching contributes to the success of unrelated donor transplantation. Blood. 2007;110(13):4576-4583. (Pubitemid 351377826)
4. Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15(12):1628-1633.
5. Przepiorka D, Weisdorf DJ, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15(6):825-828.
6. Flowers ME, Kansu E, Sullivan KM. Pathophysiology and treatment of graft-versus-host disease. Hematol Oncol Clin North Am. 1999;13(5):1091-1112. (Pubitemid 29489294)
7. Klein JP, Moeschberger ML. Survival Analysis: Techniques of Censored and Truncated Data, 2nd ed. New York, NY: Springer-Verlag; 2003.
8. Cox DR. Regression model and life tables. J R Stat Soc B. 1972;34:187-200.
9. Andersen PK, Klein JP, Zhang M-J. Testing for center effects in multi-center survival studies: a Monte Carlo comparison of fixed and random effects tests. Stat Med. 1999;18(12):1489-1500. (Pubitemid 29296604)
10. Waller EK, Langston AA, Lional S, et al. Pharmacokinetics and pharmacodymanics of antithymocyte globulin in recipients of partially matched HLA-matched blood hematopoietic pro-genitor cell transplantation. Biol Blood Marrow Transplant. 2003;9(7):460-471. (Pubitemid 38351804)
11. Remberger M, Sundberg B. Low serum levels of total rabbit-IgG is associated with acute graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation: results from a prospective study. Biol Blood Marrow Transplant. 2009;15(8):996-999.
12. Branson K, Chopra R, Kottaridis PD, et al. Role of nonmyeloablative allogeneic stem cell transplantation after failure of autologous transplantation in patients with lyphoproliferative malignancies. J Clin Oncol. 2002;20(19):4022-4031.
13. Morris E, Thomson K, Craddock C, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapse and refractory non-Hodgkin lymphoma. Blood. 2004;104(13):3865-3871. (Pubitemid 39620131)
14. Tauro S, Craddock C, Peggs K, et al. Allogeneic stem cell transplantation using a reduced intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol. 2005;23(36):9387-9393.
15. Hamadani M, Blum W, Phillips G, et al. Improved nonrelaspe mortality and infection rate with lower dose antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematological malignancies. Biol Blood Marrow Transplant. 2009;15(11):1422-1430.
16. Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: two randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 2001;98(10):2942-2947.
17. Chakraverty R, Orti G, Roughton M, et al. Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD and immune reconstitution. Blood. 2010;116(17):3080-3088.
18. Bertz H, Spyridonis A, Wasch R, Grullich C, Egger M, Finke J. A novel GVHD-prophylaxis with low-dose alemtuzumab in allogeneic sibling or unrelated donor hematopoietic cell transplantation: the feasibility of de-escalation. Biol Blood Marrow Transplant. 2009;15(12):1563-1570.
19. Finke J, Bethge WA, Schmoor C, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomized, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10(9):855-864.
20. Perez-Simon JA, Kottaridis PD, Martino R, et al. Non-myeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood. 2002;100(9):3121-3127. (Pubitemid 35217058)
21. Malladi RK, Peniket AJ, Littlewodd TJ, et al. Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced intensity conditioning sibling allo-SCT for adults with AML. Bone Marrow Transplant. 2009;43(9):709-715.